In vitro activities of 7-substituted 9-chloro and 9-amino-2-methoxyacridines and their bis- and tetra-acridine complexes against Leishmania infantum

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 1, 2003, Pages 174-180

  Di Giorgio, Carole ^a   Delmas, Florence ^a   Filloux, Nathalie ^a   Robin, Maxime ^a   Seferian, Laetitia ^a   Azas, Nadine ^a   Gasquet, Monique ^a   Costa, Muriel ^a   Timon David, Pierre ^a   Galy, Jean Pierre ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINO 2 METHOXYACRIDINE DERIVATIVE; 9 CHLORO 2 METHOXYACRIDINE DERIVATIVE; ANTILEISHMANIAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; CYTOTOXICITY; DNA METABOLISM; DNA SYNTHESIS; DRUG ACTIVITY; DRUG STRUCTURE; LEISHMANIA INFANTUM; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ACRIDINES; ANIMALS; HUMANS; LEISHMANIA INFANTUM; MEMBRANE POTENTIALS; MONOCYTES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 12244272194     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.1.174-180.2003     Document Type: Article

References (33)

1. Adams, A., J. M. Guss, W. A. Denny, and L. P. Wakelin. 2002. Crystal structure of 9-amino-N-[2-(4-morpholinyl)ethyl]-4-acridinecarboxamide bound to d(CGTACG)2: implications for structure-activity relationships of acridinecarboxamide topoisomerase poisons. Nucleic Acids Res. 30:719-725.
2. Alberti, P., J. Ren, M. P. Teulade-Fichou, L. Guittat, J. F. Riou, J. Chaires, C. Helene, J. P. Vigneron, J. M. Lehn, and J. L. Mergny. 2001. Interaction of an acridine dimer with DNA quadruplex structures. J. Biomol. Struct. Dyn. 19:505-513.
3. Antonini, I., P. Polucci, A. Magnano, and M. Sante. 2001. Synthesis, antitumor cytotoxicity and DNA-binding of novel N-5,2-di(ω-aminoalkyl)-2,6-dihydropyrazolo[3,4, 5-k]acridine-5-carbomamides. J. Med. Chem. 56:3329-3333.
4. Azas, N., C. Di Giorgio, F. Delmas, M. Gasquet, and P. Timon-David. 1997. Leishmania infantum promastigotes: flow cytometry as a possible tool for assessing the effects of drugs on cellular functions. Exp. Parasitol. 87:1-7.
5. Chen, T. K., R. Fico, and E. S. Canellakis. 1978. Diacridines, bifunctional intercalators. Chemistry and antitumor activity. J. Med. Chem. 21:868-874.
6. Crissman, H. A., Z. Darzynkiewicz, J. A. Steinkamp, and R. A. Tobey. 1990. Simultaneous fluorescent labelling of DNA, RNA, and protein. Methods Cell Biol. 33:305-314.
7. Croft, S. L., and Y. Yardley V. 2002. Chemotherapy of leishmaniasis. Curr. Pharmacol. 8:319-342.
8. Demeunynck, M., F. Charmantray, and A. Martelli. 2001. Interest of acridine derivatives in the anticancer chemotherapy. Curr. Pharmacol. Des. 7:1703-1724.
9. Denny, W. A., G. J. Atwell, B. C. Baguley, and L. P. Wakelin. 1985. Potential antitumor agents. Synthesis and antitumor activity of new classes of diacridines. The importance of the linker chain rigidity for DNA binding kinetics and biological activity. J. Med. Chem. 28:1568-1574.
10. Finlay, G. J., and B. C. Baguley. 2000. Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs. Cancer Chemother. Pharmacol. 45:417-422.
11. Fischer, C., A. Voss, and J. Engel. 2001. Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis. Med. Microbiol. Immunol. (Berlin) 190:85-87.
12. Gamage, S. A., D. P. Figgit, S. J. Wojcik, R. K. Ralph, A. Ransijn, J. Mauel, V. Yardley, D. Snowdon, S. L. Croft, and W. Denny. 1997. Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1′substituted 9-anilino-acridines. J. Med. Chem. 40:2634-2642.
13. Girault, S., S. Delarue, P. Grellier, A. Berecibar, L. Maes, L. Quirijnen, P. Lemiere, M. A. Debreu-Fontaine, and C. Sergheraert. 2001. Antimalarial in-vivo activity of bis(9-amino-6-chloro-2-methoxyacridines). J. Pharm. Pharmacol. 53:935-938.
14. Girault, S., P. Grellier, A. Berecibar, L. Maes, E. Mouray, P. Lemiere, M. A. Debreu, E. Davioud-Charvet, and C. Sergheraert. 2000. Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino6-chloro-2-methoxyacridines): influence of the linker. J. Med. Chem. 43: 2646-2654.
15. Greenspan, P., E. P. Mayer, and S. D. Fowler. 1985. Nile red: a selective fluorescent stain for intracellular lipid droplets. J. Cell Biol. 100:965-973.
16. Grimaldi, R., G. R. Tesh, and C. McMahon-Pratt. 1989. A review of the geographic distribution and epidemiology of leishmaniasis in the New World. Am. J. Trop. Med. Hyg. 41:687.
17. Herwalt, B. L. 1999. Leishmaniasis. Lancet 354:1191-1199.
18. Lagunin, A., A. Stepanchikova, D. Filimonov, and V. Poroikov. 2000. PASS: prediction of activity spectra for biologically active substances. Bioinformatics 16:747-748.
19. Le Pecq, J. B., M. Le Bret, M. Barbet, and B. P. Roques. 1975. DNA polyintercalating drugs: DNA binding of diacridine derivatives. Proc. Natl. Acad. Sci. USA 72:2915-2919.
20. Mesa-Valle, C. M., J. Castilla-Calvente, M. Sanchez-Moreno, V. MoraledaLindez, J. Barbe, and A. Osuna. 1996. Activity and mode of action of acridine compounds against Leishmania donovani. Antimicrob. Agents Chemother. 40:684-690.
21. Mrozek, A., J. Karolak-Wojciechowska, N. Bsiri, and J. Barbe. 2000. Quantitative analysis of structure-activity relationship in the acridine series. 1. Antiparasitic 9-thioaryl-acridine derivatives. Acta Pol. Pharm. 57:345-351.
22. Murray, H. W. 2000. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. Int. J. Infect. Dis. 4:158-177.
23. Ogunkolade, B. W., I. Colomb-Valet, L. Monjour, A. Rhodes-Feuillette, J. P. Abita, and D. Frommel. 1990. Interactions between the human monocytic leukaemia THP1 cell line and Old and New World species of Leishmania. Acta Trop. 47:171-176.
24. Poroikov, V. V., D. Filimonov, Y. Borodina, A. Lagunin, and A. Kos. 2000. Robustness of biological activity spectra predicting by computer program pass for non-congeneric sets of chemical compounds. J. Chem. Inform. Comput. Sci. 40:1349-1355.
25. Shapiro, H. M. 2000. Microbial analysis at the single-cell level: tasks and techniques. J. Microbiol. Methods 42:3-16.
26. Sourdon, V., S. Mazoyer, V. Pique, and J. P. Galy. 2001. Synthesis of new bisand tetra-acridines. Molecules 6:673-682.
27. Spicer, J. A., S. A. Gamage, G. J. Finlay, and W. A. Denny. 2002. Synthesis and evaluation of unsymmetrical bis(arylcarboxamides) designed as topoisomerase-targeted anticancer drugs. Bioorg. Med. Chem. 10:19-29.
28. Sundar, S. 2001. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 6:849-854.
29. Tekto, I. V., Y. Tanchuk, and A. Villa. 2001. Prediction of n-octanol/water partition coefficients from PHYSPROP database using artificial neural networks and E-state indices. J. Chem. Infect. Comput. Sci. 41:1407-1421.
30. Werbovetz, K. A., E. K. Lehnert, T. L. Macdonald, and R. D. Pearson. 1992. Cytotoxicity of acridine compounds for Leishmania promastigotes in vitro. Antimicrob. Agents Chemother. 36:495-497.
31. Werbovetz, K. A., P. G. Spoors, R. D. Pearson, and T. L. Macdonald. 1994. Cleavable complex formation in Leishmania chagasi treated with anilinoacridines. Mol. Biochem. Parasitol. 65:1-10.
32. Wilmanska, D., M. Czyz, K. Studzian, M. K. Piestrzeniewicz, and M. Gniazdowski. 2001. Effects of anticancer drugs on transcription in vitro. Z. Naturforsch. 56:886-891.
33. World Health Organization. 2002. Programme for the surveillance and control of leishmaniasis. World Health Organization, Geneva, Switzerland. [Online.] http://www.who.int/emc/diseases/leish/leishmaniasis.pdf.